Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 630 participants.

Also called NCT01192724

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 630 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01192724
Other papers using this trial's data
  • Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease American heart journal, 2014-02 DOI, PubMed 24439986

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01192724. Randomized; no masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2012-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation
Acronym
ABCD
Intervention (Drug)
Cilostazol
Intervention (Drug)
Aspirin
Intervention (Drug)
Clopidogrel
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct01192724
Content hash
9fc460e6a925b77eb0722f70638a7c2c3eef47816ca34cff339f6f0bb1281ae8